<div id="readability-page-1"><div><ul> <li>In recent days, Citigroup upgraded Penumbra from Neutral to Buy, while several other major research firms also reiterated or strengthened their positive views on the company’s prospects.</li> <li>This broad wave of analyst optimism highlights growing confidence in Penumbra’s ability to execute on its clinical, product, and international growth plans.</li> <li>Next, we’ll explore how this stronger analyst conviction may influence Penumbra’s investment narrative built around clinical data, innovation, and global expansion.</li> </ul><p>The latest GPUs need a type of rare earth metal called Terbium and there are only 36 companies in the world exploring or producing it. Find the list for free.</p><h2>Penumbra Investment Narrative Recap</h2><p>To own Penumbra, you need to believe its minimally invasive stroke and vascular therapies can keep gaining clinical and commercial traction, supported by strong evidence like STORM PE and continued global adoption. The Citi upgrade and wider analyst optimism mainly reinforce confidence around near term execution but do not materially change the key catalyst of STORM PE uptake, nor the central risk that competition and product concentration could pressure margins if rivals narrow the technology gap.</p> <p>The most relevant recent announcement to this analyst re rating is the STORM PE trial readout and Circulation publication, which provided high quality Level 1 evidence that Penumbra’s catheter directed thrombectomy improves outcomes versus anticoagulation alone in pulmonary embolism. This kind of data underpins the bullish thesis around procedure growth and reimbursement support, but also raises the stakes if competitors bring out compelling alternative devices or if future trials in other indications are less favorable.</p> <p>Yet despite growing enthusiasm around STORM PE, investors still need to be aware of how concentrated Penumbra remains in a few core franchises and...</p> <p>Read the full narrative on Penumbra (it's free!)</p><p>Penumbra's narrative projects $1.9 billion revenue and $274.7 million earnings by 2028. This requires 13.6% yearly revenue growth and about a $127 million earnings increase from $147.7 million today.</p><p>Uncover how Penumbra's forecasts yield a $309.94 fair value, in line with its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f14936e4-3033-4f42-8e8b-71422a2098b6/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f14936e4-3033-4f42-8e8b-71422a2098b6/chart/quote-price"/><figcaption>PEN 1-Year Stock Price Chart</figcaption></figure> <p>Four fair value estimates from the Simply Wall St Community range from US$108.83 to US$309.94, highlighting very different views on Penumbra’s future. When you set those side by side with the STORM PE catalyst and execution risks, it underlines why many participants are stress testing both the upside from broader adoption and the downside if competition or pricing pressure intensifies.</p><p>Explore 4 other fair value estimates on Penumbra - why the stock might be worth less than half the current price!</p><h2>Build Your Own Penumbra Narrative</h2><p>Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Penumbra research is our analysis highlighting 2 key rewards that could impact your investment decision.</li><li>Our free Penumbra research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Penumbra's overall financial health at a glance.</li></ul><h2>Looking For Alternative Opportunities?</h2><p>Opportunities like this don't last. These are today's most promising picks. Check them out now:</p><ul><li>We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</li><li>Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.</li><li>The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><p>Mobile Infrastructure for Defense and Disaster</p><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p><p>Get the investor briefing before the next round of contracts</p><p><span>Sponsored On Behalf of CiTech</span></p></div></div></div>

<p>Analysts, including Citigroup, have upgraded Penumbra to 'Buy', reflecting optimism in its global growth strategy. The focus is on Penumbra's clinical and product expansion, particularly the STORM PE trial, which shows promising results for its thrombectomy device. Despite positive forecasts, risks include competition and product concentration. Penumbra's projected revenue is $1.9 billion by 2028, requiring significant growth. Fair value estimates vary, highlighting differing views on its future. Simply Wall St provides a comprehensive analysis but advises that it is not financial advice.</p>

How Investors Are Reacting To Penumbra (PEN) Rising Analyst Optimism On Its Global Growth Strategy